|
WO2021047466A1
|
|
Crystal form of p53-mdm2 inhibitor and preparation method therefor
|
|
WO2021027503A1
|
|
Tricyclic compound, preparation method therefor, and intermediate and use thereof
|
|
WO2021042890A1
|
|
Heterocyclic compound and application thereof as trk kinase inhibitor
|
|
WO2020228729A1
|
|
Crystal form of quinazolinone compound and preparation method therefor
|
|
WO2020108154A1
|
|
Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor
|
|
WO2019214399A1
|
|
Benzo- seven-membered heterocyclic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
|
|
WO2019196918A1
|
|
Five-membered heterocyclo-pyrimidine compound, pharmaceutical composition and use thereof
|
|
KR20200115899A
|
|
Cefazedone sodium new crystal forms and method for manufacturing the same
|
|
CN111689936A
|
|
Novel dapagliflozin crystal form and preparation method thereof
|
|
EP3766883A1
|
|
Imidaxopyrolone compound and application thereof
|
|
CN111559997A
|
|
Novel dapagliflozin crystal form and preparation method thereof
|
|
CN111220737A
|
|
Method for separating ezetimibe and optical isomer thereof
|
|
SG11202004361SA
|
|
Quinazolinone compound and application thereof
|
|
CN111072667A
|
|
Five-membered or six-membered heterocyclic pyrimidine compound and application thereof
|
|
CN110734455A
|
|
novel crystal form of cefamandole nafate and preparation method thereof
|
|
CN110713491A
|
|
Synthetic method of entecavir intermediate
|
|
CN110143928A
|
|
A kind of crystal form and preparation method of key ezetimibe intermediate
|
|
CN110143972A
|
|
A kind of Cefazedone sodium novel crystal form and preparation method thereof
|
|
CN110063941A
|
|
A kind of Captopril tablets
|
|
KR20190075131A
|
|
Nitrogen-containing macrocyclic compound, its preparation method, drug composition and use
|
